Information Provided By: 
Fly News Breaks for April 19, 2016
NVTA, MYGN
Apr 19, 2016 | 11:25 EDT
Noridian, the Medicare Administrative Contractor responsible for diagnostic tests for both Myriad Genetics (MYGN) and Invitae (NVTA), priced Invitae's hereditary breast cancer panel code at $622.53, below the $950 proposed by the company, Leerink told investors earlier in a research note. While Myriad will not bill using that code, the pricing brings "sentiment risk," Leerink contends. Myriad shares are trading down over 7% to $35.84.
News For MYGN;NVTA From the Last 2 Days
There are no results for your query MYGN;NVTA
